1. Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/JAMA.2022.0003.
2. National Cancer Institute. Myeloma—Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 6 Apr 2022.
3. Myeloma incidence statistics|Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence#heading-Two. Accessed 6 Apr 2022.
4. Darzalex Assessment report-International non-proprietary name: daratumumab Procedure No. EMEA/H/C/004077/0000. https://www.ema.europa.eu/en/documents/assessment-report/darzalex-epar-public-assessment-report_en.pdf. Accessed 6 Apr 2022.
5. Overdijk MB, Jansen JHM, Nederend M, Lammerts van Bueren JJ, Groen RWJ, Parren PWHI, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813. https://doi.org/10.4049/JIMMUNOL.1501351.